Plasmodium falciparum malaria vaccines and vaccine adjuvants

Srinivasa Reddy Bonam, Laurent Rénia, Ganesh Tadepalli, Jagadeesh Bayry, Halmuthur Mahabalarao Sampath Kumar

Research output: Contribution to journalReview articlepeer-review


Malaria—a parasite vector‐borne disease—is a global health problem, and Plasmodium falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in humans. Symptoms of the disease range from mild fever and shivering to hemolytic anemia and neurological dysfunctions. The spread of drug resistance and the absence of effective vaccines has made malaria disease an ever‐emerging problem. Although progress has been made in understanding the host response to the parasite, various aspects of its biology in its mammalian host are still unclear. In this context, there is a pressing demand for the development of effective preventive and therapeutic strategies, including new drugs and novel adjuvanted vaccines that elicit protective immunity. The present article provides an overview of the current knowledge of anti‐malarial immunity against P. falciparum and different options of vaccine candidates in development. A special emphasis has been made on the mechanism of action of clinically used vaccine adjuvants.

Original languageEnglish (US)
Article number1072
Issue number10
StatePublished - Oct 2021
Externally publishedYes


  • Anti‐malarial drugs
  • Malaria vaccine
  • Plasmodium falciparum
  • Vaccine adjuvants

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Plasmodium falciparum malaria vaccines and vaccine adjuvants'. Together they form a unique fingerprint.

Cite this